iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.7249
-0.0401 (-5.24%)
At close: Jul 15, 2025, 4:00 PM
0.7190
-0.0059 (-0.81%)
After-hours: Jul 15, 2025, 5:31 PM EDT
iBio, Inc. Employees
iBio, Inc. had 16 employees as of June 30, 2024. The number of employees decreased by 10 or -38.46% compared to the previous year.
Employees
16
Change (1Y)
-10
Growth (1Y)
-38.46%
Revenue / Employee
$23,438
Profits / Employee
-$1,312,000
Market Cap
11.76M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IBIO News
- 21 days ago - iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - GlobeNewsWire
- 22 days ago - iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - GlobeNewsWire
- 4 weeks ago - iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - GlobeNewsWire
- 2 months ago - iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - GlobeNewsWire
- 2 months ago - iBio Reports Fiscal Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - iBio Raises $6.2 Million Through Warrant Inducement Transaction - GlobeNewsWire
- 3 months ago - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - GlobeNewsWire
- 3 months ago - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - GlobeNewsWire